source
- Spot Bio raises $40M to begin mRNA therapy trials for Duchenne muscular dystrophySpot Bio, a biotech startup operating in California and China, has started preclinical testing of a genetic medicine aimed at restoring the missing protein dystrophin in patients with Duchenne musc…
- FDA signals new window for companies with recent complete response letters after commissioner’s exitAfter FDA Commissioner Marty Makary left, the agency indicated it will reconsider drugs that received complete response letters in the past year. The move offers sponsors a chance to resubmit thei…